Disability

Cohere Health, Medical Mutual, and Rhyme Partner on Utilization Management Transformation

Intelligent prior authorization enables faster access to care and higher quality outcomes for members while enhancing provider experience and improving…

2 years ago

Nalu PNS System Achieves Significant and Durable Pain Reduction, Meeting the Primary Endpoint of the COMFORT RCT Study

CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical Inc. (“Nalu”) revealed significant findings from a landmark clinical trial evaluating the Nalu Peripheral Nerve Stimulation…

2 years ago

Theralase(R) Release’s 1Q2024 Financial Statements

TORONTO, ON / ACCESSWIRE / May 30, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ")…

2 years ago

AIDPH Provides Written Testimony on Senate Committee Dental Crisis Hearing

Testimony Offers Policy Solutions for Veterans, People with Disabilities, LGBTQIA+ People, and Rural CommunitiesWASHINGTON, DC / ACCESSWIRE / May 29,…

2 years ago

Assured Allies Announces a Multi-Year Partnership to Support CalPERS Long-Term Care Policyholders in Maintaining Their Independence

Assured Allies will provide the AgeAssured program to over 45,000 CalPERS policyholders for a period of at least 5 yearsAgeAssured…

2 years ago

IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757

GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics…

2 years ago

Veru to Present at the Jefferies Global Healthcare Conference

MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

2 years ago

Study in the Journal of the American Heart Association Links Hello Heart Usage to Significant Reductions in Blood Pressure, Cholesterol, and Weight

MENLO PARK, Calif.--(BUSINESS WIRE)--A new peer-reviewed study in the Journal of the American Heart Association found that Hello Heart’s digital…

2 years ago

Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome

Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X SyndromeSAN…

2 years ago